4 results
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
Assess the effect of 2 doses (10 and 20 mg) dronabinol on driving performance compared to placebo in light and heavy cannabis users. The heavy users are used as a model for chronic use of dronabinol.
Primary objective: Our key objective is to determine if a cannabinoid manipulation is more effective than a glucocorticoid manipulation to facilitate fear memory extinction retention in an experimental model of exposure therapy in healthy…
To compare event-free survival (EFS) of the experimental treatment arm including ATO/ATRA and idarubicin with standard treatment based on ATRA plus chemotherapy (AIDA regimen).